

Attorney Docket No.: **ABLE0032US.NP**
Inventors: **Urbaniak et al.**
Serial No.: **10/563,204**
Filing Date: **July 10, 2006**
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1-10 (canceled)

Claim 11 (currently amended): A method for ~~the prevention or management~~ managing or reducing the likelihood of a condition caused by exposure to an antithetical allele of a platelet by transfusion or during pregnancy, the method comprising administering to a patient ~~an immunologically effective~~ a linear peptide fragment of a human platelet antigen (HPA) recognized by T-cells.

Claim 12 (previously presented): The method according to claim 11 wherein the condition is fetomaternal alloimmune response thrombocytopenia (FMAIT), post-transfusion purpura or platelet refractoriness.

Claim 13 (canceled)

Claim 14 (currently amended): The method according to ~~claim 13~~ claim 11 wherein the HPA is selected from the group consisting of HPA-1a, HPA-1b, HPA-2a, HPA-2b, HPA-3a, HPA-3b, HPA-4a, HPA-4b, HPA-5a, HPA-5b, HPA-6a, HPA-6b, HPA-7a, HPA-7b, HPA-8a, HPA-8b, HPA-9a, HPA-9b, HPA-10a, HPA-10b, HPA-11a and HPA-11b.

Claim 15 (previously presented): The method according to claim 14 wherein the HPA has a genotype HPA-1a.

Attorney Docket No.: **ABLE0032US.NP**
Inventors: **Urbaniak et al.**
Serial No.: **10/563,204**
Filing Date: **July 10, 2006**
Page 4

Claim 16 (previously presented): The method according to claim 15 wherein the HPA-1a has sequence SEQ ID No:1, 2, 3, 4, 5, 6 or 7.

Claim 17 (previously presented): The method according to claim 11 wherein the immunologically effective platelet protein or the peptide fragment thereof is formulated for delivery through mucosal tissue.

Claim 18 (canceled)

Claim 19 (new): The method of claim 11 wherein the peptide fragment is capable of being bound by MHC molecules.

Claim 20 (new): The method of claim 11 wherein the peptide fragment is 15 amino acids in length.